Marco L. Davila

Roswell Park Comprehensive Cancer Center — United States

Medicine · Health Sciences

44h-index15.0kcitations384works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(268), Immune Cell Function and Interaction(52), Lymphoma Diagnosis and Treatment(45), Chronic Lymphocytic Leukemia Research(41), Viral Infectious Diseases and Gene Expression in Insects(38)

Publications382 total

Endogenous CD28 drives the persistent activity of CAR T cells in myeloma and lymphoma models
Blood Cancer Discovery·2026
Induction Therapy Accelerates Immune Aging in Multiple Myeloma: Implications for Cellular Therapy Readiness
Transplantation and Cellular Therapy·2026
Addressing Racial Disparities in Cellular Therapy through Race-Agnostic Predictive Modeling in Multiple Myeloma
Transplantation and Cellular Therapy·2026
Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel
Journal of the Neurological Sciences·2026
IL-36γ armored CAR T cells reprogram neutrophils to induce endogenous antitumor immunity
Cancer Cell·2025· 2 cited
Cre-dependent gene expression enables thymic development of autoreactive tumor-associated antigen targeting CAR-T cells
Molecular Therapy·2025
Supplementary Table S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S2 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S3 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S5 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S6 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S4 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Supplementary Figure S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
2025Open Access
Analysis of epidemiologic factors and treatment effects on immunophenotypes in hematologic malignancy patients
Leukemia & lymphoma/Leukemia and lymphoma·2025
Temporal control of CAR expression enables thymic generation of autoreactive T cells targeting tumor-associated antigens
Blood·2025
In-depth, quantitative characterization of important regulators and predictive biomarkers for CAR T-cell therapy induced toxicities in a clinical cohort
Blood·2025Open Access
Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling
Blood·2025
CAR T cell-driven induction of iNOS in tumor associated macrophages promotes CAR T cell resistance in B cell lymphoma
Blood·2025Open Access
Race agnostic models maintain accuracy in predicting m-protein levels in multiple myeloma
Blood·2025Open Access
IL-2 mutein-mediated improvement of CAR T function in Relapsed/Refractory diffuse B cell lymphoma
Blood·2025
page 1 of 20Next →

Frequent Co-authors

Frederick L. Locke(19), Michael D. Jain(18), Taiga Nishihori(12), Farhad Khimani(11), Rawan Faramand(10), Aleksandr Lazaryan(10), Michel Sadelain(9), Renier J. Brentjens(8), Christina A. Bachmeier(8), Bijal Shah(8), Hien Liu(8), Xuefeng Wang(7), Kayla Reid(7), Julio C. Chávez(7), Jae H. Park(6), Isabelle Rivière(6), Claudio Anasetti(6), Asmita Mishra(6), Kevin J. Curran(5), P. Maslak(5)